Skip to main content
Targeted delivery of gene therapy for cardiac reprogramming with enhanced efficacy

Targeted delivery of gene therapy for cardiac reprogramming with enhanced efficacy

Unmet Need Cardiac injury results in irreversible and permanent loss of cardiomyocytes, leading to heart failure with ~40% mortality within 4 years from diagnosis. It has been shown that directly reprogramming scar fibroblasts into new…

Read More

Adoptive T-cell immunotherapy to treat cancer caused by Epstein-Barr virus

Adoptive T-cell immunotherapy to treat cancer caused by Epstein-Barr virus

Unmet Need Epstein-Barr virus (EBV) is an infectious disease that has been shown to cause a number of cancers originating from EBV-afflicted cells. Across the globe, EBV is associated with approximately 200,000 cases of malignancies…

Read More

Anti-LYPD3 CAR T-cell therapy for the treatment of squamous cell carcinoma

Anti-LYPD3 CAR T-cell therapy for the treatment of squamous cell carcinoma

Unmet Need Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy, has proven highly effective against blood cancers such as leukemias and lymphomas. This therapy uses T-cells that are genetically engineering ex vivo to…

Read More

Structural variants of TERT in brain tumors

Structural variants of TERT in brain tumors

Unmet Need Glioblastoma is the most common type of malignant brain tumor, and accounts for 47.7% of all brain cancer cases. Despite aggressive treatment, the median overall survival for glioblastoma is 15 to 18 months.…

Read More

A novel T-cell-based immunotherapy for brain cancer

A novel T-cell-based immunotherapy for brain cancer

Unmet Need Cancer immunotherapy represents a new paradigm in cancer treatment with the goal of harnessing the immune system to selectively attack a patient’s tumor. T-cell-based immunotherapies encompass chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes,…

Read More

A humanized pro-N-cadherin antibody that can be used for treating and predicting heart failure

A humanized pro-N-cadherin antibody that can be used for treating and predicting heart failure

Unmet Need Heart failure is the leading cause of morbidity and mortality in the developed world. Approximately 50% of the US population over the age of 45 is expected to have preclinical heart failure, and…

Read More

Methods and formulation to improve cellular survival of thawing after cryopreservation

Methods and formulation to improve cellular survival of thawing after cryopreservation

Unmet Need Cryopreservation is the main method of long-term storage and transport of living cells, and it is used for cell lines and patient samples such as stem cells, CAR-T cells, bone marrow, cord blood,…

Read More

HIV treatment and prevention using broadly neutralizing antibodies

HIV treatment and prevention using broadly neutralizing antibodies

Unmet Need For over 40 years, the human immunodeficiency virus (HIV) pandemic has affected the quality of life and decreased the life expectancy for millions of people with approximately 1.5 million new cases each year.…

Read More

Dual agonist proteins for the treatment of type 2 diabetes

Dual agonist proteins for the treatment of type 2 diabetes

Unmet Need Over 37 million people in the United States have diabetes, and approximately 90-95% of them have type 2 diabetes (T2D). Diabetes and its related complications not only cause premature mortality and lower quality…

Read More

Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors

Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors

Unmet Need Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL, CD253) acts as an activator of apoptosis in many tumor cells, while remaining innocuous to normal cells. Both membrane-bound and soluble forms of TRAIL can trigger apoptosis…

Read More

Biomaterial therapy for healing brain tissue after ischemic stroke

Biomaterial therapy for healing brain tissue after ischemic stroke

Unmet Need Ischemic stroke affects 692,000 patients annually in the United States, and can result in paralysis and complications related to cognition and motor function. After a stroke, scarring and atrophy can occur at the…

Read More

Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Unmet Need In the United States alone, over 1.8 million new patients were diagnosed with cancer in 2021, and over 600,000 patients died from the disease. Cytostatic nucleotides, such as gemcitabine and 5-fluorouracil, have been…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us